

# Fundamental knowledge for nurses

## Abstract

To great promotion for nursery practice is indispensable. Knowledge for different patterns of healthcare services and nursery should be widen and more helpful. The different backgrounds and personal condition of nurses may be optimized in the clinic. This editorial addresses many interesting topic about nursery disciplines in the clinic.

**Keywords:** Healthcare, nursing, underlying diseases, pharmacology, clinical diagnosis, general practice, viral infection

Volume 8 Issue 1 - 2022

 Da-Yong Lu,<sup>1</sup> Yu-Zheng Chen,<sup>2</sup> Da-Feng Lu<sup>2</sup>
<sup>1</sup>School of Life Sciences, Shanghai University, Shanghai, China

<sup>2</sup>The Second Hospital of Neijiang District, Sichuan Province, China

**Correspondence:** Da-Yong Lu, School of Life Sciences, Shanghai University, Shanghai 200444, PRC, China, Tel 718-463-3286, Email ludayong@shu.edu.cn

Received: July 08, 2022 | Published: July 13, 2022

## Introduction

To great promotion of healthcare and medical efforts, it is indispensable for first-line nurses to knowledgeable about healthcare services and medical norms. This editorial discusses many existing clinical norm and necessity for the nurses. Several pathways and systems can promote patients' treatment outcomes by nurse activities and education.

Today, a half of major diseases are chronic diseases. Their treatments and recovery processes were getting better in the bedside (drugs, nutrition and nursery).<sup>1-12</sup> A great deal of chronic or dying patient can survive longer or high-quality life by efforts of both doctors and nursing.<sup>12-21</sup> As a result, promotion of quality of nurses knowledgeable to common medical routines is the first step. Several landscape for major medical services of different disciplines or platforms are introduced.

## Medical knowledge

High-quality of clinical nurses can be improved by educations and clinical experiences.<sup>11-38</sup> Excellent health care services require mutual trust between doctors and nurses.<sup>22-23</sup> many clinical steps are proposed (Table 1).

**Table 1** Pathways for mutual trust between doctors and nurses

Categories	Administrative
Knowledge	Communication and Sharing
Double-check	If possible
Computerization	Knowledgeable both doctors & nurses
Ethical	Clearance & mutual respects
Responsibility and salary	Heighten for nurses

In summary, different types of nursery, such as suicide prevention<sup>39-43</sup> bone diseases<sup>44-50</sup> metabolic diseases<sup>51-57</sup> neural and mental diseases<sup>58-60</sup> emergence<sup>61-65</sup> cancer<sup>66-70</sup> herbal medicine<sup>71-77</sup> and so on are reiterated. They can promote their practice by fundamental medical knowledge promotion (Table 2).

**Table 2** Basic nursery knowledge

Disciplines	Knowledge
Anatomic	Morphological understanding the origin of diseases
Physiology	Architectures of normal human activity & functionality
Clinical diagnostics	Parameters between disease and normal persons
Surgery	Conventional and machine-supportive
Biochemistry	Chemical basis of disease & treatment technology
Pharmacology	Drug selection, toxicity & doses
Law	Avoiding legislator process between hospital & patients

## Discussion

At present, world hospitals are divided into different categories. In the future, if there is a possible that different medical systems can be used for different hospitals and different patients.<sup>11</sup> Thus, optimized treatment can be provided by experienced nurses in remote hospitals and telemedicine. To remote areas of China, many new steps could be introduced.

Position suitability for different kinds of nurses having different backgrounds of education, working experience and personal conditions should be balanced in clinical treatments. Better organization of different backgrounds of nurses may be useful for promoting nursery services.

## Conclusion

Nursery service plays vital role for clinical treatments. Studying its underlying mechanisms has multiple benefiting, especially in some low-tier hospitals and healthcare centres. The education for nurses may achieve unexpected outcomes in clinical trials and patient's recovery.

## Acknowledgements

None.

## Conflicts of interest

None.

## References

1. Lu DY, Chen YZ, Lu DF, et al. Patient's care and nursery in different diseases. *Hos Pal Med Int Jnl*. 2019;3(1):28-30.
2. Lu DY, Chen YZ, Lu DF. Nursery education, capability and service promotion. *Open Access J Nursery*. 2019;2(3):1-4.
3. Lu DY, Chen YZ, Lu DF. Nursery education in schools, significance for career. *Biomed Res & Rev*. 2019;2(3):113.
4. Iqbal U, Humayn A, Li YC. Healthcare quality improvement and measurement strategies and its challenges ahead. *Int J Quality in Health Care*. 2019;31(1):1.
5. Iqbal U, Rabrenovic M, Li YC. Healthcare quality challenges in low- and middle-income countries. *Int J Qual Health Care*. 2019;31(3):165.
6. Leebov W, Scott G. Service quality improvement. The customer satisfaction strategy for healthcare. *J Healthcare Quality*. 1996;18(4):35.
7. Da-Yong LU, Chen YZ, Da-Feng LU. Nursery service, quality promotion. *Hos Pal Med Int Jnl*. 2019;3(3):97-98.

8. Ghaffari M. Building a community of learners: lessons learned. *Nurs Pract Health Care*. 2019;1(1):104.
9. Lu DY, Chen YZ, Lu DF. Nursery promotion, education and system updating. *Int J Multi Res Updates*. 2022;3(1):1–6.
10. Lu DY, Chen YZ, Lu DF. Nursery education in schools, significance for career. *Biomed Res & Rev*. 2019;2 (3):113.
11. Shamm Ahmad. An Old Disease, A New Insights. *Springer Science*. 2013;771.
12. Zimmet PZ, Magliano DJ, Herman WH, et al. Diabetes;a 21st century challenge. *Lancet Diabetes Endocrinol*. 2014;2(1):56–64.
13. Grimaccia F, Kanavos P. Cost, outcome, treatment pathways and challenges for diabetes care in Italy. *Global Health*. 2014;10(1):58.
14. Lu DY. Suicide risks and treatments, new ideas and future perspectives. *Nova Science Publishers*. 2017;1–120.
15. Lu DY. HIV/AIDS Treatments, fight for a cure. *LAMBERT Academic Publishing*. 2017;1–120.
16. Lu DY. Personalized cancer chemotherapy, an effective way for enhancing outcomes in clinics. *Woodhead Publishing, Elsevier*. 2014.
17. Lu DY, Chen XL, Ding J. Individualized cancer chemotherapy integrating drug sensitivity tests, pathological profile analysis and computational coordination—an effective strategy to improve clinical treatment. *Med Hypotheses*. 2006;66(1):45–51.
18. Lu DY, Lu TR. Drug sensitivity testing, a unique drug selection strategy. *Advances in Biomarker Sciences and Technology*. 2020;2:59–66.
19. Lu DY, Lu TR, Che JY, et al. Individualized cancer therapy, future approaches. *Current Pharmacogenomics & Personalized Medicine*. 2018;16(2):156–163.
20. Lu DY, Chen YZ, Lu DF. Nursery education, narrow-range or wide-range. *Nurse Care Open Acces J*. 2020;7(4):87–89.
21. Lu DY, Chen YZ, Lu DF. Nursery activity and quality, chemistry between doctors and nurses. *Nurse Care Open Acces J*. 2020;7(4):91–93.
22. Lu DY, Che JY, Putta S. Obese study, keep up the momentum. *Int J Endocrinol Res*. 2018;1(1):4–8.
23. Che JY, Xu B, Lu DY. Human obesity and diabetes, is it associated with COVID-19 mortality. *EC Diabetes and Metabolic Research*. 2020;4(12):1–3.
24. Lu DY, Che JY, Yarla NS, et al. Human obesity, pathological and therapeutic advances. *EC Pharmacology & Toxicology*. 2019;7(4):231–238.
25. Lu DY, Che JY, Shen Y. Clinical treatments of osteoporosis, how to target co-morbidities. *EC Orthopaedics*. 2018;9(11):781–782.
26. Lu DY, Che JY, Shen ZM, et al. Osteoporosis treatments for old people. *EC Orthopaedics*. 2019;10(5):278–280.
27. Lu DY, Zhu PP, Lu TR. Et al. The suicidal risks and treatments, seek medications from multi-disciplinary. *Cent Nerv Syst Agents Med Chem*. 2016;16(3):231–239.
28. Lu DY, Wu HY. Neuropsychiatric insights for human suicide. *Int J Scientific Res Updates*. 2021;1(2):11–18.
29. Lu DY, Wu HY, Yarla NS, et al. HAART in HIV/AIDS treatments, future trends. *Infect Disord Drug Targets*. 2018;18(1):15–22.
30. Lu DY, Wu HY, Ding J, et al. HIV vaccine for prevention and cure, a mission possible. *Rev Recent Clin Trials*. 2016;11(4):290–296.
31. Lu DY, Lu TR, Wu HY, et al. HIV/AIDS curable study, new forms of therapeutic trinity. *Rec Pat Antiinfect Drug Discov*. 2018;13(3):217–227.
32. Lu DY, Wu HY, Lu TR. HIV/AIDS treatment, therapeutic strategy break throughs. *Hos Pal Med Int Jnl*. 2020;4(2):34–39.
33. Lu DY, Che JY, Lu TR, et al. Coronavirus (COVID-19), origin, infectivity, epidemics, therapeutics and global impacts. *EC Pharmacology & Toxicology*. 2021;9(3):100–107.
34. Lu DY, Wu Hy, Yarla NS, et al. Ebola therapeutic study and future trends. *Infect Disord Drug Targets*. 2019;19(1):17–29.
35. Prityko DA, Burkov IV, Safonov VV, et al. Palliative care for children, problems and ways to solve them. *EC Clinical & Experimental anatomy*. 2019;2(9):23–29.
36. Lu DY, Chen YZ, Shen Y, et al. Medical treatment for chronic or aggressive diseases, palliative therapy and nursery. *Nov Res Sci*. 2020;3(2):556.
37. Serafini G, Salano P, Amore M. Suicidal ideation: a comprehensive overview. suicidal ideation: predictors, prevalence and prevention. *Nova Science Publishing*. 2015;1:1–42.
38. While D, Bickley H, Roscoe A, et al. Implementation of mental health service recommendations in England and Wales and suicide rates, 1997–2006: a cross-sectional and before-and-after observational study. *Lancet*. 2012;379(9820):1005–1012.
39. Lu DY, Lu TR, Lu Y, et al. Introduction for suicide study. *J Metabolic Syndr*. 2017;6(2):227.
40. Lu DY, Shen Y, Cao S. High quality treatments for human suicidal events and mortality. *Advanced Techniques in Biology & Medicine*. 2020;8(2):269.
41. Lu DY, Zhu PP, Wu HY, et al. Human suicide risk and treatment study. *Cent Nerv Syst Agents Med Chem*. 2018;18(3):206–212.
42. Melton J. Hip fracture;a worldwide problem today and tomorrow. *Bone*. 1993;14(1):1–8.
43. Silva DMW. Diagnosis of osteoporosis;bone mineral density, risk factors, or both. *EC Orthopaedics*. 2018;9(7):500–502.
44. Lu DY, Che JY, Shen Y. Osteoporosis in old women, therapeutic selection. *EC Orthopaedics*. 2018;9(7):278–280.
45. Lu DY, Che JY. Bone disease treatment, an editorial. *EC Orthopaedics*. 2020;11(8):143–145.
46. Lu DY, Che JY. Bone disease treatments, technical advances. *EC Orthopaedics*. 2020;11(10):1–3.
47. Lu DY, Che JY, Shen Y. Clinical treatments of osteoporosis, how to target co-morbidities. *EC Orthopaedics*. 2018;9(11):781–782.
48. Negm SH. The possible protective role of powder cuttlefish bone, crab shell and eggshell on osteoporotic rats. *J Food and Dairy Sci*. 2018;9(10):111–121.
49. Putta S, Peluso I, Yarla NS, et al. Diabetes mellitus and male aging, pharmacotherapeutics and clinical implications. *Curr Pharm Des*. 2017;23(41):6321–6346.
50. Lu DY, Che JY, Yarla NS, et al. Type 2 diabetes study, introduction and perspective. *The Open Diabetes Journal*. 2018;8:13–21.
51. Lu DY, Che JY, Yarla NS, et al. Type 2 diabetes treatment and drug development study. *The Open Diabetes J*. 2018;8:22–33.
52. Lu DY, Chen YZ, Lu DF. Nursery education for diabetes. *Nurse Care Open Acces J*. 2020;7(2):35–37.
53. Lu DY, Che JY, Lu Y, et al. An overview of obesity. *Metabolomics*. 2018;8(2):200.
54. Lu DY, Che JY, Wu HY, et al. Obesity, risks and managements. *Metabolomics*. 2018;8(1):156.
55. Lu DY, Che JY, Lu TR, et al. Pathology and treatments of obesity. *Trends Med*. 2018;8(5):1–2.
56. Calik T, Yalmaz V, Unalp A. Nursing approaches in pediatric epilepsy and ketogenic diet treatment. *EC Paediatrics*. 2020;7(8):110–115.

57. Lu DY, Shen Y, Xu B. Heart and brain stroke, a paramount task for emergency medication. *EC Emergency Medicine and Critical Care*. 2019;3(10):785.
58. Khan M, Silver B. Editorial: stroke in elderly: current status and future direction. *Frontier in Neurology*. 2019;10:177.
59. Lu DY, Cao S, Xu B, et al. Bone surgery with bone anatomy analysis. *EC Clinical Experimental Anatomy*. 2020;3(1):1–4.
60. Lu DY, Shen Y, Xu B. Cardiovascular emergency, future direction. *Int J Clin Med Cases*. 2020;3(3):135.
61. Lu DY, Shen Y, Xu B. Cardiovascular emergency, risk factor and improvement. *EC Emergency Medicine & Critical Care*. 2020;4(3):1–2.
62. Lu DY, Shen Y, Xu B. Brain stroke, emergency management and drug developments. *EC Pharmacology Toxicology*. 2019;7(11):1
63. Lu DY, Lu TR, Wu HY, et al. Cancer metastasis treatments. *Current Drug Therapy*. 2013;8(1):24–29.
64. Lu DY, Xu B, Ding J. Antitumor effects of two bisdioxopiperazines against two experimental lung cancer models in vivo. *BMC Pharmacol*. 2004;4:32.
65. Lu DY, Huang M, Hu CX, et al. Anti-proliferative effects, cell cycle G<sub>2</sub>/M phase arrest and blocking of chromosome segregation by probimane and MST-16 in human tumor cell lines. *BMC Pharmacology*. 2005;5:11.
66. Lu DY, Chen XL, Ding J. Treatment of solid tumors and metastases by fibrinogen-targeted anticancer drug therapy. *Med Hypotheses*. 2007;68(1):188–193.
67. Lu DY, Lu TR. Antimetastatic activities and mechanisms of bisdioxopiperazine compounds. *Anti-Cancer Agent Med Chem*. 2010;10(7):564–570.
68. Lu DY, Chen YZ, Lu TR, et al. Cancer metastasis, palliative treatment and nursery. *Annals Pharmacology Pharmaceutics*. 2020;5(1):1175.
69. Lu DY, Lu TR. Herbal medicine in new era. *Hospice Palliative Medicine International J*. 2019;3(4):125–130.
70. Yang G, Li X, Li X, et al. Traditional chinese medicine in cancer care: a review of case series published in the Chinese literature. *Evid Based Complement Alternat Med*. 2012;751046.
71. Lu DY, Lu TR, Putta S, et al. Anticancer drug discoveries from herbal medicine. *EC Pharmacology Toxicology*. 2019;7(9):990–994.
72. Pattanayak S. Alternative to antibiotics from herbal origin-outline of a comprehensive research project. *Current Pharmacogenomics Personalized Medicine*. 2018;16(1):9–62.
73. Parasuraman S. Herbal drug discovery: challenges and perspectives. *Current Pharmacogenetics Personalized Medicine*. 2018;16(1):63–68.
74. Lu DY, Lu TR. Herbal medicine in new era. *Hospice Palliative Medicine International J*. 2019;3(4):125–130.
75. Lu DY, Lu TR, Yarla NS, et al. Natural drug cancer treatment strategies from herbal medicine to chemical or biological drug. *Studies in Natural Products Chemistry*. 2020;66:91–115.